Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02294994 : Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
PhasePhase 4
AgesMin: 18 Years Max: 80 Years
Eligibility
Inclusion Criteria:

- Patients were recruited from those undergoing PCI with a planned placement of an
intracoronary stent

- Including patients with unstable angina pectoris, acute coronary syndrome or NSTEMI

- Experienced ischaemic pain at rest

- Lasting 10 minutes and occurring within 7 days before enrollment

- As well as one of the following: ECG changes: New or presumably new ST-segment
depression greater than or equal to 0.1 mV (1 mm), or transient (< 30 minutes)
ST-segment elevation greater than or equal to 0.1 mV (1 mm) in at least 2 contiguous
leads -Abnormal cardiac enzymes within the 24 hours before enrollment, defined as
elevated Troponin I defined as elevated Troponin I (above the normal reference -

- High-risk angiographic features :lesion/anatomy related bifurcation lesion, left
main lesion, multiple vessel disease, intracoronary thrombus, SYNTAX score > 26 and
chronic total occlusion disease.

Exclusion Criteria:

- Increased bleeding risk: ischaemic stroke within the last year or any previous
haemorrhagic stroke, tumour or intracranial aneurysm;

- Recent (<1 month) trauma or major surgery (including bypass surgery);

- Active bleeding

- Unexplained clinically significant bleeding, thrombocytopenia (platelet count < 100 x
109/L) or history of thrombocytopenia with GP IIb/IIIa, heparin or enoxaparin therapy

- Angina from secondary causes such as severe uncontrolled hypertension (systolic blood
pressure > 180 mm Hg despite treatment)

- Valvular disease, congenital heart disease, hypertrophic cardiomyopathy, -
Thrombolytic therapy within preceding 24 hours

- Receiving antiIIb/IIIa therapy

- Creatinine clearance of <30 mL/min
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02294994      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740